Takeda and Protagonist Submit New Drug Application for Rusfertide
Takeda (TAK) and Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA seeking approval of rusfertide for the treatment of adults with polycythemia vera. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.
